State Of Wyoming Altimmune, Inc. Transaction History

State Of Wyoming

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$5.9 - $9.45 $342 - $548	-58 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$8.69 - $12.48 $26 - $37	-3 Reduced 4.92%	58 $1,000
Q3 2021 Feb 11, 2022	SELL	$8.43 - $16.81 $1,441 - $2,874	-171 Reduced 73.71%	61 $1,000
Q2 2021 Feb 11, 2022	BUY	$9.85 - $16.46 $2,285 - $3,818	232 New	232 $2,000

191

42.4M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $317M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.